New hope for GVHD patients: experimental drug TDI01 enters human trials
NCT ID NCT06169722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called TDI01 in 60 adults with moderate to severe chronic graft-versus-host disease (GVHD), a complication of stem cell transplants. Participants have already tried 1 to 5 other treatments without success. The trial has two phases: the first checks safety and how the drug moves through the body, and the second looks at how well it controls the disease. The main goal is to see if the drug can reduce GVHD symptoms over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TDI01 (an oral drug taken once daily)
- What this could lead to
- If successful, this could offer a new treatment option for people with chronic GVHD who have not responded to other therapies.
- What could go wrong
- This is an early Phase 1/2 trial with only 60 participants, so results are preliminary. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.